Literature DB >> 8842125

Parasite antigenemia without microfilaremia in bancroftian filariasis.

G J Weil1, R M Ramzy, R Chandrashekar, A M Gad, R C Lowrie, R Faris.   

Abstract

The term "endemic normal" in the context of filariasis refers to people who are amicrofilaremic and free of clinical signs or symptoms of filariasis despite regular exposure to the parasite. Some sera from endemic normals contain soluble Wuchereria bancrofti antigens that are detectable by enzyme-linked immunosorbent assay. We now report evidence that filarial antigenemia in these people is not an artifact and that it is indicative of active W. bancrofti infection. Filarial antigenemia was first detected within one month of the onset of microfilarial patency in experimentally infected primates. Human sera from antigen-positive endemic normals contained the same filarial antigens (by Western blot) as sera from people with microfilaremia. Sera from antigen-positive endemic normals also contained significantly higher levels of immunoglobulin G4 antibodies to native and recombinant filarial antigens than sera from antigen-negative controls matched for age and sex. The epidemiology of filarial antigenemia in endemic normals was studied with sera from a population-based study of filariasis in an Egyptian village with a microfilaria prevalence of 29%. Seventeen percent of endemic normals had antigenemia, and this group comprised 11% of the total village sample. Filarial antigenemia was significantly more common in endemic normals more than 30 years of age than in younger people. These results suggest that amicrofilaremic and asymptomatic W. bancrofti infections are relatively common in endemic areas. Additional studies are needed to determine the clinical significance, prognosis, and optimal management of such infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842125     DOI: 10.4269/ajtmh.1996.55.333

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.

Authors:  Daniel J Tisch; Moses J Bockarie; Zachary Dimber; Benson Kiniboro; Nandao Tarongka; Fred E Hazlett; Will Kastens; Michael P Alpers; James W Kazura
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

2.  A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14.

Authors:  Gary J Weil; Kurt C Curtis; Peter U Fischer; Kimberly Y Won; Patrick J Lammie; Hayley Joseph; Wayne D Melrose; Norbert W Brattig
Journal:  Acta Trop       Date:  2010-04-27       Impact factor: 3.112

3.  An Expanded Transmission Assessment Survey to Confirm the Interruption of Lymphatic Filariasis Transmission in Wallis and Futuna.

Authors:  Lorenzo Pezzoli; Sung Hye Kim; Jean Pierre Mathelin; Karen Hennessey; Padmasiri Eswara Aratchige; Jayaprakash Valiakolleri
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

4.  Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.

Authors:  Didier Musso
Journal:  Pathog Glob Health       Date:  2013-03       Impact factor: 2.894

5.  Host protective immunity and vaccine development studies in lymphatic filariasis.

Authors:  M V Reddy; R Alli; B C Harinath
Journal:  Indian J Clin Biochem       Date:  2000-08

6.  Filaria associated clinical manifestations in children in an endemic area and morbidity control by immunomonitoring and optimal DEC therapy: Sevagram experience.

Authors:  B C Harinath; M V Reddy; B Bhunia; Y P Bhandari; V K Mehta; P Chaturvedi; N C Prajapati; R K Gupta
Journal:  Indian J Clin Biochem       Date:  2000-08

7.  Clinical and pathological aspects of filarial lymphedema and its management.

Authors:  R K Shenoy
Journal:  Korean J Parasitol       Date:  2008-09       Impact factor: 1.341

8.  Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria.

Authors:  Jonathan D King; Abel Eigege; John Umaru; Nimzing Jip; Emmanuel Miri; Jonathan Jiya; Kal M Alphonsus; Yohanna Sambo; Patricia Graves; Frank Richards
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

9.  Evaluation of rapid blood sample collection in the detection of circulating filarial antigens for epidemiological survey by rWbSXP-1 capture assay.

Authors:  Lawrence Ansel Vishal; Y Nazeer; Rajendran Ravishankaran; Natarajan Mahalakshmi; Perumal Kaliraj
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

10.  Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.

Authors:  Inge Kroidl; Elmar Saathof; Lucas Maganga; Petra Clowes; Leonard Maboko; Achim Hoerauf; Williams H Makunde; Antelmo Haule; Prisca Mviombo; Bettina Pitter; Neema Mgeni; Joseph Mabuye; Dickens Kowuor; Upendo Mwingira; Mwelecele N Malecela; Thomas Löscher; Michael Hoelscher
Journal:  PLoS Negl Trop Dis       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.